Register now for Aug and Sept patient conferences in Denver and Chicago.
Register now for Aug and Sept patient conferences in Denver and Chicago.

Happy Summer!

In this issue, we proudly share news of a discovery made by NETRF-funded researchers, which could change the way patients are monitored in the future. The scientists have identified new subtypes of nonfunctional pancreatic tumors with different risks of recurrence. 

If you would like to help NETRF fund more discoveries, check out several summer fundraising events to benefit NETRF and our Spark Hope campaign. Spark Hope is nearing the halfway mark—a major goal we hope to reach by the end of the summer. Please help us reach this milestone.
We invite you to make your gift online today. Your gift will be matched, doubling the impact of our research initiatives. We will keep you apprised of our progress toward this important goal in the coming weeks. 
Donate
The NETRF team experienced more heat than we expected earlier this in summer. Thanks to those of you who reached out after there was a fire in the building in which NETRF had its office.  We are all fine and appreciate your good wishes.  
Best, 

 


Elyse Gellerman
NETRF Chief Executive Officer

Research

NETRF-Funded Researchers Discover pNET Subtypes

Information May Help Predict pNET Recurrence

A group of NETRF-funded researchers has discovered molecular information that may help predict the recurrence of non-functional pancreatic neuroendocrine tumors (pNETs).  In a paper co-authored by Ramesh Shivdasani, MD, PhD, in Nature Medicine, researchers describe new subtypes of pNETs with vastly different risks of recurrence. (MORE) 

Image-Guided Chemo for NETs to Undergo Early Testing

What if you could "inject" a chemotherapeutic drug directly into a tumor, as opposed to systemic delivery through the blood, which affects all the body's fast-growing cells causing hair loss and digestive problems? That's the concept being studied by Ali Azhdarinia, PhD, University of Texas, who will use Gallium-68 dotatoc PET/CT scans to delivery targeted chemotherapy. With a new research grant, offered as part of a collaboration between NETRF and AACR, Azhdarinia will explore his ideas for minimizing damage to healthy cells and maximizing damage to cancer cells using temozolomide. (MORE)

Get Involved

Artist's Life's Work For Sale

Benefit Art Show and Sale

Carl Schaad was a talented painter. He captured landscapes and still life scenes with a magical, mesmerizing effect. In an American Impressionist style, he transports viewers to tranquil, romantic seascapes or Italian hillsides. And if he hadn't been hit by an SUV while training for a  competitive bike race, he would not have known he had neuroendocrine cancer. Eight years after his death, Carl's family has curated three decades of work for a retrospective art show, with a portion of proceeds benefiting NETRF. Read more about Carl's story and see the world as he did, with remarkable beauty. (MORE) 

Kick NET Cancer in the Butt by Kicking up Your Heels

Country Music Event Planned in Metro DC Area on August 24th  

Katherine Mueller is taking on neuroendocrine cancer. Within months of her diagnosis, she is organizing a fundraiser benefiting NETRF featuring Chad Bearden and other country music artists on Saturday, August 24, in Severna Park, MD. She is focused, determined, and empowered while also being mindful, curious, and thoughtful. Read an inspiring interview she recently gave to her local newspaper. "I will advocate for research, and most importantly, I will never stop fighting," said Katherine. See how you can buy tickets for the "Fight NET Cancer with Katherine" event. (MORE)

Education and Outreach

Coping with the Uncertainty of Cancer

How One Family Navigated NETs 

As a martial artist, Jeff Danuloff knew how to take a hit and how to come back fighting. When his life changed overnight, he had to recalibrate life as he knew it. His positive attitude and willingness to ask for help were some of the ways he improved his quality of life. Now his family wants others to know what helped them cope with the uncertainty of cancer. (MORE) 

Join NETRF at a Free Patient Conference

Denver – August 10, 2019

We invite you to join us in Denver on Saturday, August 10  for a first NETRF regional patient conference in the Mile High City. Working with experts in the Rocky Mountain region, our agenda includes Dr. Eric Liu, Dr. Lauren Fishbein, Dr. Heloisa Soares, and Dr. Mark Lewis. 

Chicago – September 14, 2019

Enjoy the end of summer in the windy city. Register for our Saturday, September 14 conference in Chicago. Co-hosted with the University of Chicago Medicine and co-chaired by Dr. Xavier Keutgen, the agenda features additional speakers from the University of Chicago Medicine, Mayo Clinic, the University of Iowa, and guest speaker Dr. Pam Kunz from the Stanford University Medical Center. 

Learn more about both of these conferences, register to attend, and reserve a hotel room.

Traveling with Cancer

Tips for a Safer Trip 

Before you set sail or take off on your dream vacation this summer, learn how you can be a cancer road warrior. You'll find all the resources you need to plan and pack medications. Plus, we offer some tried and true ways to prevent travel-related diarrhea. Make it a bon voyage! (MORE) 

NETRF Podcast Coming Soon

Be the first to listen to NETRF's new podcast about all things NET. Subscribe today so that you can be notified when we release the podcast. (MORE)
Doctor Database   Patient Groups
Newly Diagnosed   About NETs
DONATE
Facebook Twitter
Contact Us

NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston, MA 02116

(617) 946-1780 | info@netrf.org



The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.


powered by emma
Subscribe to our email list.